These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31276860)

  • 21. Autoimmune hemolytic anemia after treatment with fingolimod in a patient with multiple sclerosis (MS): A case report and review of the literature.
    Najdaghi S; Davani DN; Ghajarzadeh M; Shaygannejad V
    Autoimmun Rev; 2022 Dec; 21(12):103203. PubMed ID: 36220524
    [No Abstract]   [Full Text] [Related]  

  • 22. Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment.
    Bianco A; Patanella AK; Nociti V; De Fino C; Lucchini M; Savio FL; Rossini PM; Mirabella M
    Mult Scler Relat Disord; 2016 Sep; 9():11-3. PubMed ID: 27645336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?
    Kocyigit D; Yalcin MU; Gurses KM; Tokgozoglu L; Karabudak R
    Mult Scler Relat Disord; 2019 Jan; 27():276-280. PubMed ID: 30447536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Beadnall HN; Gill AJ; Riminton S; Barnett MH
    Neurology; 2016 Dec; 87(24):2595-2597. PubMed ID: 27856777
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
    Samaraweera AP; Cohen SN; Akay EM; Evangelou N
    Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumefactive demyelinating lesions after initiating fingolimod in patient with multiple sclerosis: A case report.
    Navardi S; Sahraian MA; Naser Moghadasi A
    Rev Neurol (Paris); 2020 May; 176(4):289-290. PubMed ID: 31668286
    [No Abstract]   [Full Text] [Related]  

  • 28. Fingolimod-associated PML in a patient with prior immunosuppression.
    Gyang TV; Hamel J; Goodman AD; Gross RA; Samkoff L
    Neurology; 2016 May; 86(19):1843-5. PubMed ID: 27164718
    [No Abstract]   [Full Text] [Related]  

  • 29. Extensive molluscum contagiosum virus infection in a young adult receiving fingolimod.
    Behle V; Wobser M; Goebeler M; Stoevesandt J
    Mult Scler; 2016 Jun; 22(7):969-71. PubMed ID: 26860987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod].
    Tanaka M
    Rinsho Shinkeigaku; 2016 Apr; 56(4):270-2. PubMed ID: 27010095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients.
    Hovi A; Airas L
    J Neuroimmune Pharmacol; 2016 Dec; 11(4):611-612. PubMed ID: 27388874
    [No Abstract]   [Full Text] [Related]  

  • 32. Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis.
    Haebich G; Mughal A; Tofazzal N
    Clin Exp Dermatol; 2016 Jun; 41(4):433-4. PubMed ID: 26577239
    [No Abstract]   [Full Text] [Related]  

  • 33. Severe lymphopenia switching from Fingolimod to Siponimod.
    Sparaco M; Miele G; Bonavita S
    Neurol Sci; 2021 Nov; 42(11):4837-4838. PubMed ID: 34390419
    [No Abstract]   [Full Text] [Related]  

  • 34. Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
    Harrer A; Wipfler P; Pilz G; Oppermann K; Haschke-Becher E; Afazel S; Kraus J; Trinka E; Sellner J
    Int J Mol Sci; 2015 Sep; 16(9):21832-45. PubMed ID: 26378517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.
    Arvin AM; Wolinsky JS; Kappos L; Morris MI; Reder AT; Tornatore C; Gershon A; Gershon M; Levin MJ; Bezuidenhoudt M; Putzki N
    JAMA Neurol; 2015 Jan; 72(1):31-9. PubMed ID: 25419615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary varicella zoster infection associated with fingolimod treatment.
    Uccelli A; Ginocchio F; Mancardi GL; Bassetti M
    Neurology; 2011 Mar; 76(11):1023-4. PubMed ID: 21403115
    [No Abstract]   [Full Text] [Related]  

  • 37. A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.
    Navardi S; Sahraian MA
    Mult Scler Relat Disord; 2018 Apr; 21():69-70. PubMed ID: 29474980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod.
    Abrahamowicz AA; Chow EJ; Child DD; Dao A; Morrison ED; Gill SK; Rogers DM; Garvin K
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33602716
    [No Abstract]   [Full Text] [Related]  

  • 39. Ventricular tachycardia after initiation of fingolimod.
    Elounais F; Aburahma A; Alkotob ML; Al Hadidi S
    BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28954755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.